I suspect Acadia and Neuren want to see trofinetide approved for Retts Syndrome without Fragile X being a distraction. Once the drug is approved, then a supplemental NDA can be applied to Fragile X which is still a rigorous process AFAIK but with the benefit of trofinetide being an already approved drug.
As to whether a Phase 3 trial will happen or not, I'd say yes it will happen.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)